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Abstract  59 
 60 
Background   61 
Self-management programs have beneficial effects on asthma control, but their implementation in 62 
clinical practice is poor. Mobile health (mHealth) could play an important role in enhancing self-63 
management.  64 
 65 
Objective 66 
To assess the clinical effectiveness and technology acceptance of myAirCoach supported self-67 
management on top of usual care in asthma patients using inhalation medication . 68 
 69 
Methods 70 
Patients were recruited in two separate studies. The myAirCoach system consisted of an inhaler 71 
adapter, an indoor air-quality monitor, a physical activity tracker, a portable spirometer, a Fraction 72 
exhaled Nitric Oxide (FeNO) device and an app. The primary outcome was asthma control; secondary 73 
outcomes were exacerbations, quality of life, and technology acceptance. In study 1, 30 participants 74 
were randomized to either usual care or myAirCoach support for 3-6 months; in study 2, 12 75 
participants were provided with the myAirCoach system in a 3 month before-after study. 76 
 77 
Results 78 
In study 1 asthma control improved in the intervention group compared to controls (ACQ difference 79 
0.70, p=0.006). A total of six exacerbations occurred in the intervention group compared to 12 in the 80 
control group (hazard ratio 0.31, p=0.06). Asthma related quality of life improved (m-AQLQ 81 
difference 0.53, p= 0.04), but FEV1 was unchanged. In study 2, asthma control improved by 0.86 82 
compared to baseline (p=0.007) and quality of life by 0.16 (p=0.64). Participants reported positive 83 
attitudes towards the system. 84 
 85 
Discussion 86 
Using the myAirCoach support system improves asthma control and quality of life, with a reduction 87 
in severe asthma exacerbations. Well validated mHealth technologies should therefore be further 88 
studied. 89 
  90 
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Highlights 91 
1. What is already known about this topic? 92 
The use of eHealth/mHealth in asthma care is upcoming. Many different apps and systems 93 
are currently available, however most systems are not evaluated in a scientific setting.  94 
2. What does this article add to our knowledge? 95 
This study shows mHealth has the potential to positively influence asthma-related 96 
outcomes. Patients are also satisfied using mHealth. 97 
3. How does this study impact current management guidelines? 98 
mHealth has the potential to transform health care delivery and should therefore be 99 
included as an effective option in future guidelines to support self-management.   100 
 101 
Key words: asthma, mHealth, app, eHealth, telemedicine, self-management, quality of life, 102 
personalized care 103 
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Introduction 127 
Self-management plays an important role in treatment for asthma (1). Effective self-management 128 
allows patients to use medication and devices correctly, acknowledge importance of lifestyle and 129 
environmental influences, recognize aggravating factors and understand the value of self-130 
monitoring. Additionally, patients need to be able to recognize and treat worsening of symptoms 131 
and know when to seek urgent medical attention (2). Therefore, asthma action plans are advised to 132 
support patients in evaluating and managing their symptoms (1).  133 
However, patient adherence to self-management programs is low, with only 20% of people 134 
reporting the use of an action plan (3). Self-management tasks are often regarded as burdensome 135 
and time-consuming while patients indicated that they would prefer different data to be added to 136 
their asthma action plan (4). Current action plans based solely on symptoms and/or lung function 137 
parameters also lack precision in detecting deteriorations in asthma control and asthma 138 
exacerbations (5). Preferably automatically collected data could improve both precision and 139 
acceptance. 140 
Mobile health (mHealth) support has the potential to transform health care delivery (6). Home-141 
monitoring applications involving mobile device-based interactive systems are promising tools for 142 
overcoming the above mentioned barriers and supporting self-management of asthma (7). mHealth 143 
can now integrate physiological, behavioral and environmental information to aid self-management. 144 
Therefore, mHealth could encourage patients to be more engaged in self-management activities, 145 
given the ease of use of their own mobile phone. 146 
There are over 500 mobile phone applications (apps) for asthma (8), but scientific evidence 147 
supporting the majority of these apps is lacking and their quality varies greatly (8, 9). Development 148 
and promotion of such apps presently does not appear to require evidence that they indeed improve 149 
asthma outcomes (10), which makes it difficult for patients and healthcare to choose the correct and 150 
effective apps for their own use (11). Huckvale reported in 2015 that 13% of the available asthma 151 
apps made recommendations about self-care procedures that were not based on scientific evidence 152 
(12). Importantly, non-evidence-based apps used as medical tools are potentially harmful (13).  153 
Therefore, the objective of the myAirCoach project was to create a validated app, that would contain 154 
elements deemed necessary by patients to aid self-management (14). We have previously reported 155 
on patients’ views on the required content of an asthma-related mHealth system (4) and assessed 156 
the feasibility and end-user experience of physiological and behavioral data collection, using already 157 
available mHealth and home-monitoring tools (15).  158 
Data from these studies were used by the myAirCoach consortium (www.myaircoach.eu) to develop 159 
a mHealth system, which included an app and several portable devices, to integrate support for 160 
important self-management aspects and tasks. The system presented data to the participant on 161 
factors, including asthma control, inhalation technique and environment exposure, thus providing 162 
patients with a wider insight into their condition and how it is affected by their environment and 163 
behavior.  164 
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In this study we assessed the clinical effectiveness of the mHealth supported myAirCoach self-165 
management system in patients with asthma compared to usual care and present the results of two 166 
linked and simultaneously performed studies.   167 
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Methods 168 
Setting and participants 169 
The myAirCoach project was EU Horizon2020 funded and conducted by a research consortium of 12 170 
collaborating partners (list of partners available at www.myaircoach.eu). Study 1, a pragmatic 171 
randomized controlled trial, registered at www.trialregister.nl (NTR 7200), was originally planned to 172 
be performed in the Netherlands and two sites in the United Kingdom (UK). The study was approved 173 
by the Medical Ethics Committee of Leiden University Medical Center and North West - Greater 174 
Manchester South Research Ethics Committee.  175 
 176 
The original sample-size calculated was based on the Asthma Control Questionnaire (ACQ). In order 177 
to detect a difference of 0.5 (SD 0.8) points with an alpha error of 0.05 and a power of 80%, the 178 
minimum sample-size needed was 41 subjects per group, 82 in total. Due to delays in obtaining 179 
ethical and MHRA approval in the UK, the UK part of the study was changed to a before-after study 180 
(study 2). 181 
   182 
Participants in both studies were eligible if they: had a clinical diagnosis of asthma; were treated 183 
with controller medication with a metered dose inhaler (GINA treatment step 2-5 (1)); had a current 184 
status of asthma with an Asthma Control Questionnaire (ACQ)-score of ≥ 1.5 (16) and/or ≥ 1 185 
exacerbations or hospital visit due to asthma in the previous year; were 18 years or older; and were 186 
able to understand Dutch or English in the respective countries. All participants provided written 187 
informed consent.  188 
Design overview 189 
Study 1 was a pragmatic randomized controlled trial in the Netherlands. Participants were included 190 
over a period of four months, while we used a fixed end date for all participants, resulting in a varied 191 
follow-up duration (3-6 months). Participants were randomized by a computerized algorithm to 192 
receive either ‘usual care’ or ‘usual care + self-management support via myAirCoach’. Study 2 was a 193 
3 month before-after study in the UK in which all participants used the myAirCoach system.  194 
All participants attended the research facility twice; once for a 30 minute introductory meeting and 195 
again at the end of the study. During these visits participants completed questionnaires and lung 196 
function (FEV1), and fraction of exhaled nitric oxide (FeNO) were measured. Participants in the 197 
intervention group in study 1 and all participants in study 2 were given instructions on how to use 198 
the myAirCoach app and different devices for self-management support, lasting approximately 1 199 
hour. In addition, all participants received periodical questionnaires through email to assess 200 
outcome parameters (see online repository). All participants continued care with their usual 201 
caregiver. 202 
Intervention 203 
The intervention was developed based on the outcomes of the focus group study and experiences of 204 
participants in the observational study (4, 15). During the development phase the research 205 
consortium had joint meetings with patient advisory forums in order to obtain feedback and 206 
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prototype improvements were made accordingly. The final integrated system consisted of several 207 
devices and an app.  208 
  209 
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Devices 210 
Both an inhaler adapter and indoor air quality monitor were designed and produced by the 211 
myAirCoach study consortium. The inhaler adapter was an add-on which fitted different sized 212 
Metered Dose Inhalers (MDI’s), with or without spacer and it connected to the myAirCoach app 213 
through Bluetooth. The inhaler adapter (see online repository figure E8) was developed to improve 214 
inhalation technique. It measured correct positioning of the inhaler during inhalation by an 215 
accelerometer. Feedback was provided with the use of indicator LED’s (red and green) on top of the 216 
inhaler adapter. In parallel, the inhaler adapter recorded sound for 24 seconds with the use of a 217 
built-in microphone. Sound analysis was performed on the order of actions (inhaling, actuation and 218 
exhaling) (17). Based on accelerometer results and sound analyses, an Inhaler Technique Score 219 
between 0-100 was calculated and provided to the participant in the myAirCoach app directly after 220 
use. If the Inhaler Technique Score was less than 100%, feedback on what could be improved was 221 
provided and the participant was redirected to an in-app manual for correct inhalation technique. 222 
The indoor air quality monitor (see online repository figure E10), registering nitrogen dioxide (NO2), 223 
Sulphur dioxide (SO2), particulate matter (PM2.5 and PM10), humidity, air pressure and 224 
temperature, was placed in the bedroom. Data, recorded every hour, was transmitted by Bluetooth 225 
to the smartphone of the participant and results were displayed in the myAirCoach app.  226 
Participants could monitor their FEV1 with a portable spirometer (nSpire Health, PiKO-1 device; 227 
available at www.nspirehealth.com) and FeNO with a home sensor (Aerocrine, NIOX VERO device; 228 
available at www.niox.com). The results were shown on the displays of the devices and participants 229 
were asked to manually enter results in the app. 230 
The Fitbit Charge HR (Fitbit, Inc, Fitbit charge HR; available at http://www.fitbit.com) is a wearable 231 
fitness tracker, measuring steps and stairs walked, calories burned and real-time heart rate. 232 
Participants were advised to wear the Fitbit continuously. Heart rate and steps data were shown in 233 
the myAirCoach app.  234 
 235 
myAirCoach app 236 
At the first visit, participants downloaded the myAirCoach app on their smartphone. Since the app 237 
was only used in a research setting and required anonymity, the app was not publicly available, but 238 
could only be downloaded with the help of the research team. Every participant was also given an 239 
anonymous username and password and logging in was required the first time they used the app. In 240 
the app, results from all devices were displayed in graphs. Additionally, participants were able to 241 
monitor symptoms with questionnaires, including the Asthma Control Diary (ACD) (18), Asthma 242 
Control Questionnaire (ACQ) (19) and Sino-Nasal Outcome Test-22 (SNOT-22) (20) (see online 243 
repository table E2). Outdoor air quality, measured by the European Copernicus Program 244 
(www.regional.atmosphere.copernicus.eu), was also displayed for current location or other favorite 245 
locations. A map using color-coding to indicate levels of pollution was provided in addition to an 246 
overall statement on air pollution and concentrations of ozone, ultra-fine dust, fine dust, carbon 247 
monoxide, NO2 and SO2. More detailed information on the app and devices is provided in the online 248 
repository (including figure E4-E9). 249 
  250 
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Outcomes and follow-up  251 
For both studies the primary outcome was asthma control assessed by the Asthma Control 252 
Questionnaire (ACQ, range 0-6; Minimal Clinically Important Difference (MCID) = 0.5) at 4-week 253 
intervals (19). A lower score represents better asthma control.  254 
Secondary outcomes were severe asthma exacerbation rate, quality of life, FEV1 and technology 255 
acceptance. Severe exacerbations were defined as asthma-related hospitalizations, emergency care 256 
visits or systemic use of oral corticosteroids for ≥3 days (21). Asthma related quality of life was 257 
measured by the mini Asthma Quality of Life Questionnaire (m-AQLQ]; MCID = 0.5 (22)), consisting 258 
of four domains: symptoms, activities, emotions and environment, at 12-week intervals. Generic 259 
health-related quality of life was assessed by the EQ-5D-5L questionnaire at 12-week intervals (23). 260 
FEV1 was measured with the PiKO-1 device throughout the study for the intervention participants 261 
and during the visits for the controls. Participant attitudes towards and acceptance of the 262 
technology were measured by the Technology Acceptance Questionnaire (TAQ) at 12-weeks (24). 263 
The TAQ has eleven domains next to specific questions about the inhaler adapter and the PiKO-1 264 
device (see online repository).  265 
 266 
Statistical analysis 267 
In study 1 the outcomes of the ACQ, m-AQLQ, EQ-5D-5L and FEV1 were analyzed using a mixed 268 
model analysis, adjusting for repeated measurements within participants, and baseline values of the 269 
outcomes. Severe exacerbation rates were compared by the Cox proportional hazard model, 270 
allowing analysis of multiple exacerbations per participant. For study 2 paired t-tests were 271 
performed for the ACQ, m-AQLQ, EQ-5D-5L and FEV1 comparing baseline measurements with the 272 
final results. Boxplots for the TAQ were made, combining results of all participants using the system 273 
in both study 1 and 2. All analyses were performed with STATA 14.0 (StataCorp, College Station, TX). 274 
  275 
12 
 
Results 276 
Subjects 277 
Thirty participants were included in study 1 and twelve participants in study 2 (see online repository 278 
figure E1). The major reason for declining participation was concern about time. Two participants 279 
dropped out of study 1, one in the intervention group due to ‘personal circumstances’ and one 280 
control (no further response to repeated enquiry). Mean follow-up in the intervention group was 281 
166 days and in the control group 154 days. All participants from study 2 finished follow-up with a 282 
mean follow-up of 94 days.  283 
Baseline characteristics are shown in table 1. There were no significant differences between control 284 
and intervention groups in study 1. Participants in study 2 had a slightly different profile than 285 
participants of study 1. They were on average 10 years younger, their age of diagnosis was also 286 
lower, FeNO was higher and their baseline ACQ was better.     287 
System use   288 
The app was used for 2345 tasks. These tasks included filling out questionnaires and entering 289 
FeNO/FEV1 data (see online repository table E1). In study 1 on average 110 tasks per patient were 290 
performed and in study 2 this was on average 67 times.  291 
The number of inhalation registered by the system in study 1 was 219 inhalations/patient and in 292 
study 2 this was 81 inhalations/patient. In study 1 the Inhaler Technique Score changed by 1% (from 293 
79% to 80%). In study 2 the Inhaler Technique Score changed from 88% to 76%. 294 
Outcomes 295 
The intervention group had a clinically relevant and statistically significant improvement of asthma 296 
control compared to the control group in study 1. In the mixed-model analysis, the difference in ACQ 297 
was 0.70 (95%CI -1.21; -0.20, p=0.006) (table 2). A sensitivity analysis additionally adjusting for 298 
baseline characteristics age, smoking status, age of diagnosis and gender and a sensitivity analysis 299 
for baseline FEV1 and FeNO showed similar results. In study 2 asthma control improved by 0.86 300 
(95%CI 0.29; 1.44, p=0.007) compared to baseline, as shown in figure 1.  301 
The number of severe exacerbations was lower in the intervention group compared to the control 302 
group for study 1 (respectively, 6 vs 12 (hazard ratio 0.31, 95%CI 0.09; 1.06, p=0.06), see figure 2). 303 
Exacerbation rate for intervention participants was 0.94 per participant per year, compared to 2.04 304 
per participant per year for the participants in the control group. In study 2, three exacerbations 305 
occurred. Exacerbation rate was 1.06 per participant per year. 306 
The difference in m-AQLQ assessed by the mixed-model analysis was 0.53 (95%CI -0.22; 1.10, 307 
p=0.04) (figure 3). The differences in the subdomains ‘symptoms’ and ‘emotions’ both exceeded the 308 
MCID of 0.5 and were statistically significant (online repository table E3; figure E11). In study 2, the 309 
participants had a baseline m-AQLQ of 5.13 and their score increased by 0.16 (p=0.64). The 310 
participants improved in all domains, with the largest improvement in the ‘emotions’ domain. 311 
The EQ-5D-5L showed an improvement in generic health-related quality of life in the intervention 312 
group (coefficient 0.12, p=0.04) in study 1 compared to the controls. In study 2 there was no 313 
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significant difference in EQ-5D-5L score between baseline and exit (0.04, p=0.23), as shown in figure 314 
E2.  315 
There was no change in FEV1 measured in both studies. In study 1 the FEV1 was 0.09 liters (p=0.60) 316 
lower in the intervention group compared to the control group (see figure E3). In study 2 317 
participants had a baseline FEV1 of 2.63L and their exit FEV1 was 2.52L (p=0.42). 318 
The TAQ showed  favorable attitudes of the participants towards the myAirCoach intervention 319 
except for the impact of the system on social influence and attitude towards the inhaler adapter. 320 
Participants were most positive on the facilitating conditions and trust in the system. They also 321 
reported favorable attitudes on the self-management aspect of the system. The average domain 322 
scores are depicted in the figures below (Figure 4).   323 
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Discussion 324 
Our study shows that mHealth supported self-management aided by the myAirCoach system was 325 
effective in clinically improving asthma control, exacerbation-rates and quality of life. Additionally, 326 
end-users of this mHealth platform reported generally positive attitudes towards the system.  327 
In asthma, most research in eHealth has focused on using traditional forms of telemedicine, 328 
including remote consultations and SMS reminders (25-27). Even though Huckvale et al. already 329 
reported 764 different asthma apps in 2015 (12), the number of trials focusing on mobile app 330 
assisted self-management in asthma is limited (28). Moreover, none of the apps assessed in previous 331 
studies additionally used such diverse data from wearables, environmental databases and home-332 
monitoring devices (29). As a consequence of our multi-faceted intervention, we opted to assess 333 
clinical outcomes, such as asthma control and exacerbation rate. Other studies have focused more 334 
on outcomes particularly relevant for medication adherence. For example, the recent ADAPT study 335 
by Kosse et al. developed an app with several modules primarily targeting adherence in adolescents 336 
and they showed that their app indeed improved this (30).   337 
A Cochrane review in 2012 (updated in 2013) included only two studies regarding asthma self-338 
management with apps compared to paper-based asthma self-management (31). Ryan et al. 339 
concluded that monitoring of asthma through mobile phone use does not improve asthma outcomes 340 
more than paper based strategies (32). Both groups showed clinically relevant improvements in 341 
asthma control and quality of life. It is suggested that monitoring in itself could have a positive effect 342 
on asthma related outcomes. However, paper monitoring could be more cumbersome and time-343 
consuming for the participant and it does not allow for collection of other types of data, such as 344 
heart rate. mHealth is more user-friendly since a majority of the adults uses a smartphone (33). 345 
A study by Cook was a promising proof of concept study showing the effectiveness of an asthma 346 
related mHealth application (34). The asthma related outcomes (asthma control and FEV1) improved 347 
and patients were satisfied with the intervention. This study however only consisted of an 348 
intervention group without randomization. Our study supports and extends these findings since we 349 
have found a beneficial effect on asthma control, severe asthma exacerbations and quality of life 350 
and we included a control group in the first study to minimize the effect of confounding factors 351 
unrelated to the mHealth. We also reported a high user-satisfaction. 352 
An important aspect of the myAirCoach project was the involvement of participants in different 353 
stages of the development of our intervention, including repeated device testing to improve 354 
performance. We specifically asked what kind of functionalities they wanted to see in a mHealth 355 
system and what they deemed useful information. If no device existed that could measure these 356 
parameters, we developed it within our study consortium. Overall, the participants were satisfied 357 
with the system and they reported they felt the system aided them in their self-management. We 358 
believe that this early involvement of patient users in this project has helped in devising a user-359 
friendly tool for self-management of asthma. 360 
An important strength of our study is that we provided participants with an app which included a 361 
wide variety of data on very different aspects of asthma management. The app was used often, with 362 
110 tasks per patients on average in study 1 and 67 tasks per patient in study 2. We were only able 363 
to record a task if the participant manually entered data into the app (answering a questionnaire, 364 
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entering a measurement). So, the average numbers of tasks indicates the minimal usage, since any 365 
other action in the app (e.g. viewing of inhalation score, air quality data or individual graphs on 366 
symptoms and measurements) was not recorded.  367 
Although we showed that by providing a comprehensive overview we managed to improve asthma 368 
control, exacerbation rate and quality of life, we do not know how much each of the individual 369 
components contributed to these improvements. This also relates to the fact that we did not record 370 
viewing of results in the app of, for example, the inhalation technique score. We know this improved 371 
in some and worsened in others. However, we do not know who actually viewed their inhalation 372 
technique results in the app, or  who acted upon these results, for example by viewing the in-app 373 
inhalation instructions or by going to their healthcare professional. Different components are 374 
relevant for different patients. In future studies we recommend to also systematically collect data on 375 
page-views and time spent on different components of an app and preferably also on subsequent 376 
self-management changes made by patients.  377 
An important limitation of the study is the number of participants included in the study. In the 378 
original protocol the intention was to include 90 participants in the study (45 intervention and 45 379 
control). Due to the fixed end date of the study appointed by the EU, combined with strict regulatory 380 
laws regarding studies with medical devices in the UK and longer than expected development time 381 
of the app and devices, we were only able to include 30 (randomized) participants in the study site in 382 
the Netherlands. All UK participants were allocated to the use of the myAirCoach system in order to 383 
get as much feedback on the system as possible in a before-after study setting. Even though the 384 
amount of participants included in the RCT was limited, the primary outcome parameter improved. 385 
One might argue that this might be due to overestimation of the real effect, also known as the 386 
winner’s curse. However, since most secondary outcomes also showed a consistent improvement 387 
and the effect was still statistically significant after correction for multiple tests we are confident 388 
that the myAirCoach system had a positive effect on asthma related outcomes.  389 
Another limitation is the lack of long-term data of the system. Participants in the Netherlands used 390 
the system for a maximum of 6 months. Even though participants reported in the TAQ that they 391 
were willing to continue using the system, it is unknown if the positive effects on asthma control 392 
would be sustained after a longer period. Another important aspect is the influence of seasonal 393 
factors on the results of our study, since we do not have a year follow-up time. Next, in 74% of the 394 
inhalation no inhalation technique score could be calculated due to technical issues, possibly 395 
explaining the negative attitudes of the patients towards the inhaler add-on in the TAQ. 396 
Even though the age of participants was highly variable (23 to 77 years old), future studies are called 397 
for to further evaluate mHealth systems in larger and more diverse groups. In future projects 398 
predictive modelling could be used to make personalized recommendations given by the system to 399 
further enhance self-management.  400 
  401 
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Conclusion  402 
We have shown a clinically significant beneficial effect of the myAirCoach mHealth intervention on 403 
asthma related outcomes. Asthma control, quality of life and exacerbation-rate improved during the 404 
study. Overall, participants were satisfied with the myAirCoach study app and intervention. 405 
Data availability 406 
Data analyzed in this manuscript are available upon request.  407 
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Figure legends 493 
 494 
Fig. 1 Asthma Control Questionnaire 495 
Asthma control measured by ACQ. Lower score represents better asthma control (MID=0.5). Note: 496 
not all participants finished 6 months follow-up due to a fixed end date ; mean follow-up was 149 497 
days (5 months) in study 1. A questionnaire filled in within 14 days of enrollment is regarded as 498 
baseline. In study 1, 28/30 participants finished 12 weeks follow-up and 5 participants (17%) had 499 
more than 24 weeks follow-up. Error bars represent 95%CI. Points in the graph have been shifted 500 
slightly to the left or the right in order to avoid overlap of error bars.  501 
 502 
Fig. 2 Time until first exacerbation per participant 503 
Proportion exacerbation plotted against follow-up time. The numbers depicted in the graph indicate 504 
the participants still in follow-up.  505 
 506 
Fig. 3 Mini Asthma Quality of Life Questionnaire 507 
Asthma related quality of life measured by the m-AQLQ. Higher score represents better quality of 508 
life (MID=0.5). Note: not all participant finished 6 months follow-up in study 1. Error bars represent 509 
95%CI. Points in the graph have been shifted slightly to the left or the right in order to avoid overlap 510 
of error bars. 511 
 512 
Fig. 4 Boxplots of the Technology Acceptance Questionnaire domains 513 
Thirteen domains of the Technology Acceptance Questionnaire tested in both studies combined.  514 
Patients reported how much they agreed with the questionnaire statements on a 7-point Likert scale 515 
(ranging from completely disagree =1 to completely agree =7). The higher a score, the more 516 
favorable the attitudes of the participants towards the myAirCoach system were. In the figure all 13 517 
domains are plotted and the scores are depicted on the y-axis of every boxplot.  518 
 519 
  520 
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Table 1. Participant demographics  521 
 Study 1 
(RCT in the Netherlands) 
Study 2 
(before-and-after 
study in the UK) 
 Control 
(n=15) 
Intervention 
(n=15) 
p value  
(n=12) 
Age, mean (SD) years* 49.1 (11.0) 51.3 (13.2) 0.65 41.3 (13.8) 
Gender, n female* 11 12 0.68 10 
Internet experience, n**   0.27  
• None  0 1   
• A little  1 1   
• Quite a lot  2 6  2 
• A lot  11 7  10 
Smoking, n**   0.14  
• Yes  0 0  1 
• No 11 7  10 
• Previously 4 8  1 
Season enrolled, n**   0.66  
• Winter  2 1  0 
• Spring 11 13  0 
• Summer  2 1  12 
GINA medication step, n**   0.25  
• 2 0 3  1 
• 3 8 6  2 
• 4 0 1  1 
• 5 2 2   
Severe exacerbations 
previous year ,n ** 
13 14 0.54 8 
Age at diagnosis, mean (SD) 
years* 
26.1 (18.6) 19.5 (21.1) 0.39 16.4 (18.4) 
FEV1, median (IQR) L*** 2.3 (1.4-2.9) 2.1 (1.5-3.0) 0.85 2.5 (1.9-3.4) 
FeNO, median (IQR), parts 
per billion*** 
18 (13-28)  14 (12-22) 0.45 17 (11.5-54) 
ACQ, mean (SD) score* 2.31 (0.97) 2.33 (0.78) 0.94 1.59 (0.88) 
• Controlled (n) 0 0  3 
• Partly controlled (n) 3 3  3 
• Uncontrolled (n) 11 11  6 
SNOT22, mean (SD) score* 35.9 (18.4) 40.4 (17.9) 0.52 27.9 (12.0) 
* calculated with t-test 522 
**calculated with chi
2
 523 
***Mann-Whitney U test   524 
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Table 2. Outcome measures.  525 
 Study 1 Study 2 
 Difference 
intervention-control 
p value Difference  
exit-baseline  
p value 
ACQ , score -0.70 0.006 -0.86 0.007 
m-AQLQ, score 0.53 0.04 0.16 0.64 
EQ-5D-5L, score 0.12 0.04 0.04 0.23 
FEV1, liters -0.09 0.60 -0.11 0.42 
Differences as assessed by mixed model analysis, adjusting for repeated measurements within 526 
participants, and baseline values of the outcomes. 527 




1 
 
Online Repository Text 
Flowchart participant inclusion 
 
  
2 
 
Generic health-related Quality of life 
 
 
  
3 
 
Lung function 
 
  
4 
 
Devices and app 
The app could be downloaded if the participant had an android phone. If participants used Apple’s 
iPhone, the app could not be installed on their smartphone since every iPhone is linked with a 
personal Apple account (Apple ID), which prevents anonymous processing of data, because all 
recorded data is also shared with Apple. Therefore, participants with an iPhone were given an iPod 
Touch with an anonymous Apple ID specifically created for this study. The iPod Touch was a 6th 
generation iPod that works in a similar fashion as the iPhone these participants normally used.  
When the app was opened, participants could navigate to one of the five menu’s: ‘Dashboard’, 
‘Measurements’, ‘Calendar’, ‘Messages’ and ‘Me’. The menu ‘Dashboard’ (figure E4) was divided into 
five tabs (at the top of the screen) of which ‘At a Glance’ was the main screen. Here participants 
could see a quick summary of the most recent measurements in a general overview. In the second 
screen named ‘Action Plan’ an asthma action plan was shown to the participants. In the third tab 
‘Questionnaires’ participants could fill out the ACD, ACQ or SNOT22  questionnaires. The following 
two tabs ‘Goals’ and ‘Notifications’ allowed participants and health care providers to set 
personalized goals (for example: amount of steps a day) and receive (update) notifications. In the 
screenshots below demo scores are depicted as an illustration.  
The second menu at the bottom was ‘Measurements’ (figure E5), which was divided in three main 
categories: ‘Health’, ‘Activity’ and ‘Environmental’. In ‘Health’ participants could see an overview of 
their personal scores of Inhaler Use, FeNO, Spirometry and their questionnaires (ACD/ACQ, SNOT22). 
In ‘Activity’ participants could see an overview of their Fitbit data. In ‘Environmental’ participants 
were able access air quality data for outdoor air quality (www.regional.atmosphere.copernicus.eu) 
and indoor air quality (measured by the Indoor air quality monitor).  
Participants could select every individual measurement to see an overview over time (see figure E6). 
Mean scores were calculated and displayed in a visual manner. More detailed information about 
individual measurements was available by pressing the ‘all data’ button. 
In the ‘Calendar’ participants were shown measurements in a Calendar to more easily identify days 
with worse (or better) asthma control, as well as to have a complete overview and history of their 
actions. Participants could also manually enter notes about specific events in order to facilitate in 
recollecting these details when discussing their asthma with a healthcare professional a few months 
later (a feature specifically requested by participants) (4).  
In the ‘Messages’ tab participants could chat in real-time with the research team. In possible future 
projects participants could use this function to chat with their own healthcare provider. The final tab 
‘Me’ was a settings function with guides for the app, inhalation technique instruction material and 
links to useful websites on asthma. In this tab participants could also enable or disable the virtual 
support “Airica” (figure E7) which recognized voice commands and text inputs. Airica is based on 
artificial intelligence, such as machine learning algorithms and natural language processing concepts. 
The inhaler add-on shown in the picture below (figure E8) was an add-on to normal MDI’s. After 
activation the device by shaking it, it connected to the app. A screen would pop-up and sound 
recording would start, which is shown in figure E9 . After sound recording was finished, data was 
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uploaded, processed and then sent back to the app. A score was calculated varying from 0% to 100% 
and displayed to the participant.  
The indoor air quality monitor (air quality sensor) was a black cube connected through Bluetooth 
with the smartphone and the app. It was roughly 7cm x 7cm x 7cm (figure E10). Data was recorded 
every hour, temporarily stored on an internal memory and transmitted to the phone when available. 
Participants were asked to hold their smartphone at least daily within Bluetooth vicinity of the 
indoor air quality monitor to allow data transfer. 
   
Table E1. Number of times the app was used to perform tasks. 
 Study 1 Study 2 Total  
ACD 130    177 307 
ACQ 70 27 97 
Feno 570 213 783 
SNOT22 67 34 101 
Spirometry 700   357 1,057 
Total 1,537 808 2,345 
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Activities 
Participants were asked to fill out questionnaires and do measurements frequently. Questionnaires 
not described in this manuscript are: the Food Frequency Questionnaire (GA2LEN FFQ), Hospital 
Anxiety and Depression Scale (HADS), Health Education Impact Questionnaire (heiQ), Sino-Nasal 
Outcome Test (SNOT-22) and Cost-Q. The Asthma Control Diary (ACD) is a questionnaire comparable 
to the ACQ, except it asks questions about the previous day (compared to the previous week). 
 
Table E2. Study procedures  
Frequency of tests 
First 
visit 
INTERVENTION CONTROL 
Final  
visit 
1-2 wk 
training 
phase  Follow-up 
1wk test 
phase 
Follow-up 
Patient Questionnaires 
ACD or ACQ  Once Daily Monthly - Monthly Once 
Current medication 
record 
Once Daily Monthly - Monthly Once 
Exacerbations history  Once Daily Monthly - Monthly Once 
m-AQLQ Once - 3-monthly - 3-monthly Once 
GA
2
LEN FFQ  Once - - - - - 
HADS Once - - - - - 
heiQ Once - 3 months - 3 months Once 
SNOT-22 Once - Monthly - Monthly Once 
EQ-5D-5L Once - 3-monthly - 3-monthly Once 
Cost-Q  - - 3-monthly - 3-monthly Once 
Technology Acceptance 
Questionnaire  
 - 3 months - - Once 
Physiological sensors 
Portable spirometry Once Daily Weekly - - - 
FeNO Once Daily Weekly - - Once 
Heart Rate and activity 
level  
Once Continuous Continuous - - 
- 
Monitors 
Inhaler usage monitoring Once Continuous Continuous - - - 
External environmental 
monitoring  - 
Continuous Continuous - - - 
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m-AQLQ domains 
 
The m-AQLQ can be divided in 4 domains: symptoms, activities, emotions and environment (Table 
E3; figure E11) . In study 1 improvements in ‘symptoms’ and ‘emotions’ were both clinically and 
statistically significant. Improvements in the ‘environments’ domain also exceeded the MCID.  
 
Table E3. Quality of life per domain.  
   Study 1* Study 2⊺ 
 Difference  P value Change  P value 
Domain      
• symptoms 0.69 0.03  0.22  0.51 
• activities 0.32 0.41  0.10 0.83 
• emotions 0.54 0.04  0.25 0.44 
• environment 0.53  0.08  0.03 0.94 
*study 1. RCT: intervention compared to controls with mixed-model analysis 
⊺ study 2. Before-and-after study: baseline compared to end of follow-up with paired t-test 
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Technology Acceptance Questionnaire (TAQ) 
The twelve domains of the TAQ are: 
- Performance expectancy: the degree to which participants believe that using the system will 
help them attain gains or make losses with the performance of their health management 
- Effort expectancy: the degree of ease associated with the use of the system 
- Social influence: the degree to which participants perceive that important others believe 
they should use the system  
-  Facilitating conditions: the degree to which participants believe that there are objective 
factors available in their environment to support their use of the system 
- Affect: participants’ overall affective reaction towards using the system 
- Self-efficacy: the degree to which participants judge themselves capable of using the system 
to manage their health 
- Trust: the degree to which participants believe that using the system will occur in a safe and 
reliable manner 
- Behavioral  intention: the degree to which an individual intends to use of the myAirCoach 
system for managing their health 
- Motivation: the degree to which an individual is motivated to continue the myAirCoach 
system for managing their health 
- Self-management: participants’ opinion on conducting self-management through the system 
- Inhaler adapter: participants’ opinion on the myAirCoach inhaler adapter 
- PiKO-1: participants’ opinion on the PiKO-1 home spirometer 
- Time: the degree to which an individual is satisfied with the amount of time is takes to use 
the system  
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Captions  
 
Fig. E1 Flowchart participant enrollment 
Study 1 is shown on the upper panel (A) and study 2 on the lower panel (B). 
 
 
Fig. E2 EQ-5D-5L 
Generic health-related quality of life measured by the EQ-5D-5L questionnaire. 
 
Fig. E3 FEV1 
Home-measured FEV1 by the intervention patients in study 1 and patients from study 2 with use of 
the PiKO-1.   
 
Fig. E4 myAirCoach app: Dashboard 
Different aspects of the myAirCoach app: ‘At a glance’, ‘Action Plan’, ‘Questionnaires’, ‘Goals’, and 
‘Notifications’.  
 
Fig. E5 myAirCoach app: Measurements 
Various categories of measurements are presented to the participant: ‘Health’, ‘Activity’, and 
‘Environmental’. 
 
Fig. E6 myAirCoach app: Display of the gathered data 
Various visualization capabilities of the collected data via the mobile app. 
 
Fig. E7 myAirCoach app: Airica 
Virtual assistant based on artificial intelligence and natural language processing. 
Fig. E8 myAirCoach inhaler add-on 
The inhaler add-on was capable of measuring several critical parameters, such as correct positioning 
of the inhaler during inhalation as well as the sound of the inhalation procedure. 
 
Fig. E9 myAirCoach app: Inhalation recording 
Audio recording and related feedback to the participant 
 
Fig. E10 myAirCoach air quality monitor  
The indoor air quality monitor is capable of measuring several indoor parameters such as nitrogen 
dioxide (NO2), Sulphur dioxide (SO2), particulate matter (PM2.5 and PM10), humidity, air pressure 
and temperature.  
 
Fig. E11 m-AQLQ domains  
The m-AQLQ divided in the four domain: symptoms, activity, emotions and environment. 
